Physician profile
Gideon P Ewing
NPI 1558418426
$15,363.50
in general payments reported to CMS, 2019-2025
63 companies · $2,846 in 2025
The $2,846 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,046 · 2020: $465 · 2021: $1,937 · 2022: $2,939 · 2023: $2,444 · 2024: $2,688 · 2025: $2,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,876 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,876.06 |
| Education | $100.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,390.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,275.52 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $1,088.26 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Pfizer INC. | $1,064.98 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $822.29 | 2019-2025 | Ninlaro, Iclusig, Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $701.40 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Janssen Biotech, INC. | $627.04 | 2019-2025 | Talvey, Darzalex, Tecvayli |
| Genentech USA, INC. | $540.06 | 2019-2025 | Venclexta, Polivy, Columvi |
| Abbvie INC. | $513.17 | 2019-2025 | |
| Amgen INC. | $435.99 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Celgene Corporation | $416.67 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Lilly USA, LLC | $400.07 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Seagen INC. | $365.03 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Gilead Sciences, INC. | $324.88 | 2019-2025 | Trodelvy |
| Daiichi Sankyo INC. | $312.74 | 2019-2025 | Enhertu, Datroway |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $291.87 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.17 | 2019-2025 | Gilotrif |
| Myriad Genetic Laboratories, INC. | $286.31 | 2022-2024 | Bracanalysis Cdx, Myrisk |
| Array Biopharma INC | $284.07 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Regeneron Healthcare Solutions, INC. | $273.75 | 2019-2025 | Libtayo |
| Genzyme Corporation | $269.28 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $263.95 | 2019-2025 | |
| Incyte Corporation | $238.62 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $200.65 | 2019-2023 | Imbruvica, Epkinly |
| Pharmacosmos Therapeutics INC. | $188.51 | 2022-2025 | Monoferric |
| Alexion Pharmaceuticals, INC. | $176.63 | 2019-2024 | Ultomiris |
| Astellas Pharma US INC | $170.05 | 2021-2025 | Xtandi |
| Stemline Therapeutics INC. | $166.28 | 2022-2025 | Orserdu |
| Blueprint Medicines Corporation | $159.05 | 2021-2024 | Ayvakit |
| Sobi, INC | $156.97 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $114.42 | 2020-2022 | |
| Beigene USA, INC. | $103.85 | 2023-2025 | Brukinsa |
| Myovant Sciences INC. | $100.53 | 2021-2022 | |
| Kyowa Kirin, INC. | $99.36 | 2019-2025 | Poteligeo |
| Glaxosmithkline, LLC. | $95.34 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Exelixis INC. | $89.16 | 2019-2025 | Cabometyx |
| Kite Pharma, INC. | $88.93 | 2021-2025 | Yescarta |
| Sumitomo Pharma America, INC. | $85.82 | 2023-2025 | Orgovyx |
| Dova Pharmaceuticals | $78.89 | 2019-2021 | |
| Servier Pharmaceuticals LLC | $74.87 | 2024-2025 | |
| Epizyme, INC. | $56.84 | 2021 | |
| Fresenius Kabi USA, LLC | $54.61 | 2024-2025 | Stimufend |
| Emd Serono, INC. | $54.42 | 2019-2022 | |
| Deciphera Pharmaceuticals INC. | $54.07 | 2021-2025 | Qinlock, Romvimza |
| Beone Medicines USA, INC. | $53.92 | 2025 | Brukinsa, Tevimbra |
| Janssen Pharmaceuticals, INC | $48.16 | 2019 | |
| Puma Biotechnology, INC. | $43.18 | 2020-2024 | |
| Clovis Oncology, INC. | $41.47 | 2020-2022 | |
| Tolmar Pharmaceuticals, INC. | $37.75 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $33.02 | 2020 | |
| Pharmaessentia USA Corporation | $31.79 | 2023 | Besremi |
| Global Blood Therapeutics, INC. | $30.39 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $25.25 | 2022 | |
| Tersera Therapeutics LLC | $23.66 | 2025 | Quzyttir |
| Progenics Pharmaceuticals, INC. | $22.05 | 2022 | |
| Novocure INC. | $21.54 | 2022 | |
| Immunocore Limited | $20.01 | 2025 | Kimmtrak |
| Jazz Pharmaceuticals INC. | $19.59 | 2022 | |
| Caris Mpi, INC. | $14.78 | 2025 | Mi Cancer Seek |
| Mylan Institutional INC. | $13.44 | 2021 | |
| Rigel Pharmaceuticals, INC. | $12.35 | 2022 | |
| Verastem, INC. | $12.30 | 2020 | |
| Secura Bio, INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gideon Ewing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.